Anshul Maheshwari Sells 2,441 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 2,441 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.14, for a total transaction of $36,956.74. Following the completion of the sale, the chief financial officer now owns 204,241 shares of the company’s stock, valued at $3,092,208.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Tuesday, April 2nd, Anshul Maheshwari sold 2,425 shares of SI-BONE stock. The stock was sold at an average price of $15.45, for a total value of $37,466.25.

SI-BONE Price Performance

SIBN traded down $0.21 on Friday, reaching $14.92. The company’s stock had a trading volume of 333,933 shares, compared to its average volume of 419,487. SI-BONE, Inc. has a 1 year low of $13.96 and a 1 year high of $29.51. The business’s 50 day moving average is $15.44 and its 200 day moving average is $17.89. The company has a current ratio of 9.76, a quick ratio of 8.75 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, February 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. SI-BONE had a negative return on equity of 25.14% and a negative net margin of 29.93%. The company had revenue of $38.86 million for the quarter, compared to the consensus estimate of $38.60 million. Research analysts anticipate that SI-BONE, Inc. will post -0.95 EPS for the current fiscal year.

Institutional Investors Weigh In On SI-BONE

Hedge funds and other institutional investors have recently bought and sold shares of the business. Kent Lake Capital LLC increased its holdings in shares of SI-BONE by 5.3% in the 1st quarter. Kent Lake Capital LLC now owns 421,305 shares of the company’s stock valued at $6,897,000 after acquiring an additional 21,305 shares during the last quarter. Silvercrest Asset Management Group LLC increased its holdings in shares of SI-BONE by 13.8% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 1,060,937 shares of the company’s stock valued at $17,368,000 after acquiring an additional 128,702 shares during the last quarter. Bellevue Group AG increased its holdings in shares of SI-BONE by 810.5% in the 1st quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock valued at $18,661,000 after acquiring an additional 1,014,756 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of SI-BONE by 7.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company’s stock valued at $336,000 after acquiring an additional 1,372 shares during the last quarter. Finally, EntryPoint Capital LLC increased its holdings in shares of SI-BONE by 78.4% in the 1st quarter. EntryPoint Capital LLC now owns 13,906 shares of the company’s stock valued at $228,000 after acquiring an additional 6,113 shares during the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on SIBN shares. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price objective on shares of SI-BONE in a research note on Tuesday, May 7th. Morgan Stanley reduced their price target on shares of SI-BONE from $26.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 7th. Piper Sandler started coverage on shares of SI-BONE in a research report on Thursday, March 28th. They issued an “overweight” rating and a $25.00 price objective for the company. Truist Financial reaffirmed a “buy” rating and set a $24.00 price target (down from $26.00) on shares of SI-BONE in a research report on Tuesday, February 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $27.00 price objective on shares of SI-BONE in a research report on Tuesday, May 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, SI-BONE currently has an average rating of “Buy” and a consensus target price of $27.29.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.